Safety of intranasal corticosteroid sprays during pregnancy: an updated review
Rhinitis and rhinosinusitis are commonly encountered in pregnant women. Intranasal corticosteroid (INCS) sprays are generally safe and effective in the treatment of these conditions in the general population. However, the use of some of these INCS sprays during pregnancy is still controversial.
To review the current literature about the safety of intranasal corticosteroid sprays during pregnancy.
Using different search engines, each type of INCS was reviewed separately (triamcinolone, beclomethasone, budesonide, fluticasone propionate, fluticasone furoate, mometasone, and ciclesonide). A total of 51 full-length articles were examined for eligibility. After applying inclusion and exclusion criteria, a total of three articles were reviewed.
No significant association with congenital organ malformations has been linked to intranasal use of beclomethasone, budesonide, fluticasone propionate, fluticasone furoate, or mometasone. Intranasal triamcinolone, however, has been found to have a significant association with respiratory tract defects. Data about the safety of intranasal ciclesonide during pregnancy are not available.
Lacking sufficient clinical trials on the use of intranasal corticosteroid sprays in pregnancy, we suggest that the intranasal use of fluticasone furoate, mometasone, and budesonide is safe if they are used at the recommended therapeutic dose after a proper medical evaluation. Intranasal fluticasone propionate might be a safe option in the absence of other INCS options due to its questionable efficacy during pregnancy. Risk-benefit ratio should always be considered before prescribing any intranasal corticosteroid sprays during pregnancy.
KeywordsIntranasal Corticosteroids Safety Pregnancy Rhinitis Sinusitis
Compliance with ethical standards
No funding was received for this study.
Conflict of interest
Authors have no conflict of interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 12.Mak KK, Ku MS, Lu KH et al (2013) Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol 54:239–245. doi: 10.1016/j.pedneo.2013.01.007 CrossRefPubMedGoogle Scholar
- 16.Sheikh A, Panesar SS, Salvilla S (2009) Ear, nose, and throat disorders Hay fever in adolescents and adults Ear, nose, and throat disorders Hay fever in adolescents and adults. BMJ clinical evidenceGoogle Scholar
- 18.Fokkens W, Lund V, Mullol J (2012) European position paper on rhinosinusitis and nasal polyps. Rhinology 1–136. doi: 10.4193/Rhino50E2
- 28.Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration. doi: 10.1371/journal.pmed.1000100
- 32.Pelucchi Foresi a, Gherson A G, et al (1996) Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 98:274–282CrossRefPubMedGoogle Scholar
- 33.Daley-Yates PT, Price AC, Sisson JR et al (2001) Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51:400–409. doi: 10.1046/j.0306-5251.2001.01374.x CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Kallen B, Rydhstroem H, Aberg A (1999) Congenital malformations after the use of inhaled budesonide in early pregnancy. Am J Obstet Gynecol 93:392–395Google Scholar
- 37.Renu Lal Pharm.D (2015) Drugs in pregnancy and lactation: improved benefit-risk information. Food and Drug Administration (FDA) https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf. Accessed 24 Jan 2017
- 42.Thorsson L, Borga O, Edsbacker S (1999) Systemic availability of budesonide after nasal administration of three different formulations; pressurized aerosol, aqueous spray pump and powder. Br J Clin Pharmacol 47:619–624. doi: 10.1046/j.1365-2125.1999.00956.xf CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Nave R, Herzog R, Laurent A, Wingertzahn MA (2009) Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy vol. Clin Ther 31:2988–2999. doi: 10.1016/j.clinthera.2009.12.002 CrossRefPubMedGoogle Scholar